Obesity

Two injectable medications with a tape measure wrapped around them

Biotech

Gubra reveals early data for once-weekly obesity asset

Gubra’s once-weekly obesity candidate was tied to 3% weight loss during a six-week phase 1 trial, with most adverse events "mild" and "transient."

Gabrielle Masson Nov 13, 2024 5:56pm

money cash coins dollars

Metsera follows phase 1 weight loss data with $215M series B

Nov 13, 2024 9:15am

AstraZeneca still 'playing to win' in obesity, execs say

Nov 4, 2024 11:49am

Graphic of two hands shaking under a red and purple light

In $285M deal, Novo taps Ascendis to help create monthly GLP-1

Nov 4, 2024 8:43am

viking ship long boat chase race water sunset

Viking oral obesity med posts 6.8% weight loss for highest dose

Nov 4, 2024 7:30am

scary haunted house at night

Alnylam abandons clinical-stage Type 2 diabetes asset

Oct 31, 2024 10:27am